ENDRA Life Sciences Inc. - NDRA STOCK NEWS

ENDRA Life Sciences (NASDAQ: NDRA) reported Q3 2024 financial results and business updates. The company accelerated enrollment in its global multisite pilot study, with nearly 40 subjects enrolled in the past two months. Operating expenses decreased 52% to $1.5 million compared to Q3 2023, achieving $3.1 million in annualized savings. Net loss was $2.4 million, including a $911,000 non-cash charge. Cash position stood at $4.7 million as of September 30, 2024.

The company enhanced its TAEUS platform with AI and machine learning features, expanded its patent portfolio to 82 issued patents globally, and activated a system at LMU University Hospital in Germany for clinical evaluation.

ENDRA Life Sciences (NASDAQ: NDRA) announced the acceptance of a poster presentation at The Liver Meeting 2024, showcasing their TAEUS technology's capability to measure liver fat in high-BMI patients. The study demonstrates TAEUS's ability to obtain liver fat measurements in patients with BMI over 35, including cases where BMI exceeded 40 and the liver was more than 40mm below the skin surface. The presentation, titled 'Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity,' will be presented at the AASLD conference in San Diego from November 15-19, 2024.

ENDRA Life Sciences (NASDAQ: NDRA) has been granted its 17th European patent (EP4247282) for a novel method of monitoring tissue temperature during minimally invasive thermal surgical procedures using their TAEUS® system. The patent relates to monitoring tissue ablation and enables integration with existing ablation systems. The technology is applicable to microwave and radiofrequency thermal ablation procedures, which are growing globally as less invasive alternatives to open surgery. This addition brings ENDRA's global intellectual property portfolio to 82 issued patents across key markets including the United States, Europe, and China.

ENDRA Life Sciences (NASDAQ: NDRA) has initiated a post-CE mark clinical study for its TAEUS liver system at LMU University Hospital in Munich, Germany. The study aims to assess TAEUS' liver fat measurement capabilities against the gold standard MRI-PDFF test. LMU researchers plan to present findings at future medical congresses and publish in peer-reviewed journals.

This collaboration is expected to:

• Build upon ENDRA's growing portfolio of clinical data
• Support the company's FDA De Novo submission targeted for mid-2025
• Support the adoption of TAEUS technology as a reliable and accurate biomarker for liver fat
• Mark a strategic entry into Germany's healthcare market, the largest in Europe

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has been granted an extension by Nasdaq to regain compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. The company now has until November 20, 2024 to evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive trading sessions. This extension does not immediately affect ENDRA's listing or trading status, and its stock will continue to trade under the symbol 'NDRA'.

Additionally, ENDRA reported that 91% of the Series B Warrants issued in their June 2024 public offering have been exercised, resulting in the issuance of 15,831,864 new shares of common stock. This brings the company's total outstanding common shares to 17,280,655.

ENDRA Life Sciences (NASDAQ: NDRA) reported Q2 2024 financial results and provided a business update. Key highlights include:

1. New executive team: Alexander Tokman appointed as acting CEO, along with new CFO and Head of Regulatory and Clinical Affairs.

2. Clinical and regulatory progress: Advanced U.S. FDA process, initiated new pilot clinical trials, and expanded patent portfolio to 81 issued patents globally.

3. Financial updates: Raised $8.0 million in a public offering and reduced annualized operating expenses by $3.1 million.

4. Q2 2024 financials: Operating expenses decreased to $2.2 million from $3.0 million in Q2 2023. Cash and cash equivalents were $6.4 million as of June 30, 2024.

The company is prioritizing clinical data collection for a new De Novo FDA filing and revisiting its go-to-market strategy for TAEUS technology.

ENDRA Life Sciences Inc. (NASDAQ: NDRA) has announced a 1-for-50 reverse stock split effective August 20, 2024. This move aims to increase the bid price of its common stock to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 72.4 million to 1.4 million, with authorized shares decreasing from 1 billion to 20 million. Trading will continue under the symbol 'NDRA' on a split-adjusted basis. Stockholders' fractional shares will be rounded up to the nearest whole share. The company's transfer agent, VStock Transfer, , will manage the process for stockholders of record, while those holding shares through brokers will have their positions adjusted automatically.

ENDRA Life Sciences (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), has rescheduled its second quarter conference call to August 22, 2024, at 4:30 p.m. Eastern time. The call was previously set for August 14, 2024. ENDRA will file its quarterly report on form 10-Q with the SEC as planned and issue a press release summarizing financial and operating results for Q2 2024 on the day of the call.

Participants can pre-register for the call using a provided link to receive a unique PIN for immediate access. Those unable to pre-register can dial (844) 868-8846 (U.S.) or (412) 317-5465 (International). A webcast will be available on ENDRA's Investor Relations page. A telephone replay will be accessible until August 29, 2024, and a webcast replay will be available shortly after the call.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced significant leadership changes. Alexander Tokman, a board member with 24+ years of global commercial leadership experience, has been appointed as acting CEO, replacing Francois Michelon. The company also added two industry veterans to key roles: Ziad Rouag as Head of Regulatory and Clinical Affairs and Richard Jacroux as Chief Financial Officer.

Tokman brings extensive experience in driving revenue growth and implementing improved strategies for startups and established companies. He aims to focus on core regulatory and commercial activities to secure approval and launch ENDRA's patented technology. Rouag's expertise in regulatory affairs will support TAEUS's domestic regulatory process, while Jacroux's financial management experience will aid in scaling the business.